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NeuronAdult cells from patients can be reprogrammed to induced pluripotent stem cells (iPSCs) which
successively can be used to obtain speciﬁc cells such as neurons. This remarkable breakthrough
represents a new way of studying diseases and brought new therapeutic perspectives in the ﬁeld
of regenerative medicine. This is particular true in the neurology ﬁeld, where few techniques are
amenable to study the affected tissue of the patient during illness progression, in addition to the
lack of neuroprotective therapies for many diseases.
In this review we discuss the advantages and unresolved issues of cell reprogramming and neu-
ronal differentiation. We reviewed evidence using iPSCs-derived neurons from neurological
patients. Focusing on data obtained from Parkinson’s disease (PD) patients, we show that
iPSC-derived neurons possess morphological and functional characteristics of this disease and build
a case for the use of this technology to study PD and other neuropathologies while disease is in pro-
gress. These data show the enormous impact that this new technology starts to have on different
purposes such as the study and design of future therapies of neurological disease, especially PD.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
 Stem cells. Deﬁnition and classiﬁcation. The notion of
pluripotency.
 Pluripotent stem cells: embryonic and induced pluripotent
stem cells.
 Embryonic stem cells: origin and applications.
 Induced pluripotent stem cells: origin, current and future
applications.
Stem cells have two main characteristics: the ability of
self-renewal and the capacity to differentiate into specialized cell
types. These two features confer them the possibility to generate
differentiated cells that could be used in basic and translational
research and cell therapy strategies. Cell potency is deﬁned as
the cell’s ability to differentiate into other cell types [66].
Stem cells can be divided into three main groups according to
their potency: totipotent stem cells which have the capacity todifferentiate into all cell types including extra-embryonic cells;
pluripotent stem cells which have the potential to differentiate
into all somatic cell types and multipotent stem cells, such as adult
stem cells, which can only generate specialized cells types of their
own speciﬁc lineage [29].
Embryonic stem cells (ESCs) are pluripotent cells found in the
inner cell mass of the blastocyst, originated by the union of the
oocyte with the spermatozoid. These cells originate all cell types
of an organism, e.g., more than 200 cell types in humans [46].
ESCs can be cultured and expanded in vitro [83]. This possibility
has enthused numerous research groups to use ESCs as cellular
sources of differentiated cells, the required cellular substrate for
regenerative medicine [17,29]. However, fertilized oocytes are
the source of human ESCs, which is a matter of ethical concerns
in some countries. This issue, the availability of the starting mate-
rial and possible immunogenicity differences between the
ESC-derived cells and the recipients that could potentially lead to
immunological rejection, have hampered the successful exploita-
tion of this type of stem cell for the beneﬁt of patients [77].
The way a cell possesses or acquires pluripotency capacity as
been a topic of intense research. Physiologically, cytoplasmic fac-
tors of the oocyte are capable to modify (or reprogram) the nucleus
of a spermatozoid to originate a fertilized egg, which will become a
blastocyst, the prime source of ESCs. Experiments of somatic clon-
ing and cell fusion between oocytes and adult cells generated
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adult nucleus, supporting the idea that factors present in the
oocyte cytoplasm were able to provide pluripotency properties to
adult cells ([20] reviewed in [75,89,45,29]).
In 2006, Takahashi and Yamanaka, based on information
provided by more than 40 years of previous research (reviewed
in [52]), selected 24 genes as candidates to mediate cell repro-
gramming to a pluripotent state. In a seminal work that paved
the way for the winning of the 2012 Nobel Prize of Medicine and
Physiology, they proved that the exogenous expression of four
genes (Oct4, Sox2, c-Myc and Klf4) was able to convert ﬁbroblasts
into pluripotent stem cells [82]. These pluripotent stem cells orig-
inated from adult cells were called induced pluripotent stem cells
(iPSCs) and were able to originate all three germ lines (mesoderm,
endoderm and ectoderm) and contribute to germ line transmission
in the mouse [82,75].
The development of this newmethod, which allows the produc-
tion of stem cells with similar pluripotency properties than ESCs,
represents the beginning of a new era for basic and translational
research with great perspectives in clinical treatment [89].
iPSCs have the potential to provide all specialized cell types of a
given organism for regenerative therapies without the previously
mentioned shortcomings of ECSs. Moreover, since iPSCs can be
obtained from the same patient, immunological issues would be
prevented using this strategy [10,59]. Alternatively, since donors
can be selected beforehand according to their HLA signature, a
country-speciﬁc collection of iPSCs, compatible to that country
population, can be generated as a source of HLA-compatible cell
substrates [85]. For example, it has been calculated that 50
homozygous HLA types selected from 24000 donors could match
90.7% of the Japanese population [48]. Similarly, as few as 10
homozygous cell types, selected from 10000 donors, could provide
compatible cell substrates at the HLA-A, HLA-B and HLA-DR levels
for transplantation of 37.7% of the UK population [85]. In
Argentina, it has been calculated that 33 and 106 selected donors
could provide histocompatible cells to 50% or 90% of the
population, respectively (C. Gamba, personal communication).
Furthermore, a global initiative to enable the interchange of
HLA-typed iPSCs worldwide in resemblance of the Bone Marrow
Worldwide Registry is underway and Argentina is part of it. We
believe that this initiative will have a major impact in the
next-generation, iPSCs-based cell therapies to come since it can
provide HLA-matched cells worldwide for allogeneic transplanta-
tion [72].
Still, many bottlenecks remain for most of these foreseeing
therapeutic interventions. In particular, for some specialized cells,
cell culture protocols are lacking the needed efﬁciency and
GMP-compatible procedures to be translated to a clinical setting.
Notwithstanding the expected high impact of this technology
on future treatments, one immediate application for iPSCs came
from the realization that specialized cells originated from patients
using reprogramming technology possess characteristics of the
disease affecting that patient, in particular if the disease has a
genetic component [15]. In other words, by cell reprogramming
and differentiation, we can model and study diseases that were
not amenable to research before. This holds true especially for neu-
rological diseases of genetic origin where neurons from patients
have been shown to mimic pathological features of the diseases.
Translationally, this technique allows identifying potential tar-
gets for future therapies in these in vitro models of disease.
Moreover, iPSCs cells from patients can be generated and differen-
tiated into specialized cells of interest and used as platforms for
drug assessment, where screening tests of several compounds will
give relevant data about toxicity and therapeutic efﬁcacy of each
drug. Thus, this new approach could improve the accuracy of drugdevelopment and therefore enhance the probability of successful
therapies [89,29].
In this review, we will discuss critical issues for the translation
of the iPSC technology to the beneﬁt of neurological patients, i.e.,
the reprogramming techniques themselves, the advantages and
shortcomings of available protocols for neuronal differentiation
from iPSCs and its application in neurological disease modeling.
We will focus on the evidence obtained from iPSC-derived neurons
from PD patients and the validation of this technology to study PD
and other neurological disorders.
2. Methods of cellular reprogramming
In order to achieve optimal iPSCs various cellular reprogram-
ming techniques were developed, including the use of viral vectors
(Moloney leukemia virus (MLV)-retroviral, lentiviral, adenoviral,
Sendai virus-derived vectors, among others), non-integrative plas-
mids, proteins, miRNA, mRNA, small molecules, etc [44,29,18]. In
the present review we will be focusing on two types of reprogram-
ming systems widely used for academic purposes (MLV-retroviral
and lentiviral vectors) and two systems, more amenable to be used
in a clinical setting (non-integrative plasmids and proteins).
2.1. Retroviral vectors I: MLV-derived
The ﬁrst reprogramming protocol described used 4
MLV-derived retroviral vectors to express each of the 4 nowadays
called Yamanaka reprogramming factors in murine cells.
This approach yielded 0.02% of ES-like cells from MEFs after
introduction of the four reprogramming factors selected [82,54].
Using this delivery system, the ﬁrst hiPSCs generation from
adult human ﬁbroblasts was achieved in 2007 by S. Yamanaka’s
group with iPSC colonies appearing between 25 and 30 days
post-infection with a reprogramming efﬁciency of 0.01–0.02%
[81,44].
The ﬁrst years after reprogramming was described, much of the
research effort was focused on increasing reprogramming
efﬁciency. Later, it was realized that, even using the less efﬁcient
MLV-derived reprogramming protocols, enough iPSCs clones could
be obtained for further characterization. In the practice, the
selection and characterization of bona ﬁde hiPSCs is cumbersome
and time-consuming and therefore, a surplus of iPSCs is usually
obtained even when using low efﬁciency protocols.
The amount of each reprogramming factor expressed determi-
nes several features of the iPSCS generated [25,43,24]. This variable
is difﬁcult to control using 4 retroviral vectors for each reprogram-
ming gene. The capacity of MLV-derived vectors to accommodate
only a limited size of transgenes (aprox. 6 kb) precludes the
expression of all 4 genes in one vector backbone [1]. This limitation
was overcome by the group of G. Mostoslavsky by developing a
system based on another type of retroviral (lentiviral) vectors,
which can express the 4 factors simultaneously (STEMCAA).
2.2. Retroviral vectors II: lentiviral vectors
A lentivirus-derived system was designed by G. Mostoslavsky’s
group to express a single multicistronic transcript which contains
all the reprogramming [25,74] factors (see Fig. 1). This new vector
named, ‘‘stem cell cassette’’ (STEMCCA), allows iPSCs generation
with a minimal numbers of viral integrations which increase the
safety of reprograming method and the reproducibility of the
amount of expression of each reprogramming factor [74]. This
strategy appears to be more efﬁcient and safer, since previous
reports using the multiple vectors system have required more than
15 viral integrations to accomplish cellular reprogramming. This
Fig. 1. Illustration of steps and cellular products of the reprogramming and the differentiation process towards neuroepithelium or DA neurons. (A) Time schedule of cell
reprogramming. D0, ﬁbroblast seeding, D1 cell transduction with lentiviral vectors, D7, cell passage, D20 to D45, manual selection of iPSC clones according to morphology. (B)
Representative photograph of ﬁbroblasts (40). (C) Scheme of the STEMCAA vector. (D) iPSC colony obtained according to Sommer et al. [74]. (E) Representative images
illustrating a neuroepithelium culture obtained according to Lancaster et al. [36]. (F) Representative images illustrating DA differentiation of hNSCs using PA6-CM or deﬁned
medium according to [42,55] Neurons and dopaminergic neurons are seen by TUJ-1 and TH immunoﬂuorescence analysis, respectively. Hoechst staining indicates the
nucleus. Magniﬁcation: 40.
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reprogramming efﬁcacy [74] and nowadays the STEMCCA vector
is widely used with reprogramming efﬁciencies of 0.1–1.5%
[44,29] (see Fig. 1 for illustrative purposes).
Another advantage of the system is based on the fact that len-
tiviruses allow the transduction of both dividing and
non-dividing cells, being therefore a more suitable system for
reprogramming of quiescent cells [74].
Nevertheless, this system has several disadvantages inherent to
all retroviral-basedmethods. The risk of insertionalmutagenesis is a
major concern when iPSC-derived cells are being considering for
clinical applications, providing increased difﬁculties at the regula-
tory level. In order to increase the safety of the iPSC obtained, aSTEMCCA versionwas engineeredwith LoxP sites. Using this vector,
iPSCs free of reprogramming factors were obtained by transient
transduction with a defective adenovirus or a episomal plasmid
which expresses Cre-recombinase. This strategy does not solve the
regulatory problem entirely, since it leaves a bit more than 200 bp
of the original STEMCAA sequence in the host genome [73,2,44].
2.3. Plasmid constructs
Recently, seeking to establish an approachmore prone to clinical
translation, several research groups have sought new reprogram-
ming methods by transferring non-integrative constructs such as
expression plasmids containing the 4 reprogramming genes.
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embryonic ﬁbroblasts (MEFs) with repeated transient transfections
of two plasmids, one of them containing Oct3/4, Sox2, and Klf4
cDNAs and the second one expressing c-Myc. Expression of
endogenous pluripotent genes and teratoma development
analysis of the iPSCs obtained with this method suggested that
non-integrating vectors can also successfully induce cellular
reprogramming [53,76,44]. This represents an advantage since
the possibility of genomic integration is lower than other methods.
Moreover, transient transfections are technically less complicated
and safer than viral vector manipulation.
However, reprogramming efﬁciencies are lower (0.001–
0.0001%) than the ones obtained by integrating vectors (0.1–1%).
This low efﬁciency could be partially caused by insufﬁcient time
of expression of the reprogramming factors, which is needed to
complete the epigenetic modiﬁcations instrumental for cellular
reprogramming. Even with the implementation of several rounds
of transfection, the reprogramming efﬁciencies values remained
low.
A year later, Kaji and colleagues have reprogrammed murine
and human ﬁbroblasts using a Cre/loxP-based system. The con-
struction was a single plasmid which contained a cassette with
the four reprogramming factors and 2A peptides, ﬂanked with
loxP sequence. This strategy allows transgenes excision after
cellular reprograming through Cre transfection. Analysis for
endogenous pluripotency markers demonstrated that the loss of
exogenous reprogramming factors did not affected the repro-
grammed state of iPSCs cells [30,54]. In fact, it has been shown that
after pluripotency is achieved by the expression of the exogenous
reprogramming factors, the host cells shuts down the exogenous
expression and induces the endogenous expression of the repro-
grammed genes [75]. This endogenous expression is crucial to
maintain long-term pluripotency in culture of the iPSCs generated
and allows the correct, unbiased differentiation of these cells
towards the desired phenotype.
Alternatively, other systems were designed, such as the episo-
mal vector oriP/EBNA1 (Epstein Barr nuclear antigen-1). This con-
struction, derived from Epstein Barr virus, expresses the four
reprogramming factors, the transgene Lin28 and SV40 large T anti-
gen [50]. However, this new alternative had low reprogramming
efﬁciency in human ﬁbroblasts. Nevertheless, this system allows
the generation of iPSCs from peripheral blood or CD34 positive
cells from cord blood, with efﬁciencies of 0.02 and 0.009% respec-
tively on day 14 post-transfection, suggesting that this technique
could be useful for cell reprogramming of these speciﬁc cells
[44,50].
For clinical applications, safer methods are required to
minimizing alterations of iPSCs genome and possibilities of tumor
formation. The last described, non-viral techniques are interesting
options to achieve this goal.
2.4. Protein cell reprogramming
Another approach is based on cellular reprogramming with pro-
teins as reprogramming factors. As a proof-of-principle, MEF cells
were reprogrammed using a fusion protein which contained the
four reprogramming factors with a poly-arginine protein transduc-
tion domain [92].
A new alternative based on recombinant proteins from an
Escherichia coli expression system was used on murine and human
ﬁbroblasts. However, this method had showed low reprogramming
efﬁcacy [44]. An important factor is related to the protein
expression system selected for reprogramming factors synthesis.
Mammalian expression systems are capable of producing
correct protein folding, assembly and post translational modiﬁca-
tion. Kim and colleagues generated iPSCs using recombinantreprogramming factors obtained from a stable HEK293 human cell
line. However, it required several rounds of transduction and
8 weeks to achieve cellular reprogramming [32,39].
Other system, based on cell-permeable reprogramming pro-
teins, was used on human dermal ﬁbroblasts. Stem cell-like colo-
nies which resembled embryonic stem cells features were
generated. However, they failed to expand as iPSC or ESC lines [41].
Disadvantages such as low reprogramming efﬁciency together
with technical issues related to the system of protein expression
selected, large-scale production, protein puriﬁcation and
characterization suggest that more studies are needed in order to
analyze the potential application of protein-based reprogramming
approaches.
In relation with cell differentiation and reprogramming meth-
ods, Rhee and colleagues analyzed cell death and senescence in
neural precursors (NPs) derived from iPSCs generated by different
methods of cellular reprogramming. Interestingly, they observed
that NP cells from iPSCs obtained by cell reprogramming based
on direct delivery of poly-arginine-tagged reprogramming factors
were expandable for several passages without detection of senes-
cence. In contrast, residual expression of exogenous reprogram-
ming genes was detected in NP cells derived from iPSCs
generated by retroviral or lentiviral cell reprograming methods.
They also observed cell death and senescence in NP cells at low
passages. However, tumor formation was observed in one condi-
tion of cell transplantation of mature dopaminergic neurons
derived from iPSCs generated by poly-protein-cell reprogramming
technique. This was related to a high number of undifferentiated
cells detected into the graft [61].
As a cautionary note, independently of the reprogramming
method use, it is important to notice that bona ﬁde iPSCs need to
pass several quality control tests in order to be deﬁned as such.
The burden impose to the dynamics of the cell genome, inevitable
creates unstable cells that need to be discarded from downstream
applications. These controls include tests for transgene silencing
and integration, stemness, pluripotency, normal and stable kary-
otype, viability after freezing and thawing, maintenance of stem-
ness and genomic stability after long-term culture, among others.
In addition, epigenetic memory, i.e., the remaining epigenetic sig-
nature from the donor cell could be problematic, especially if
iPSCs are used at early passages [4,19]. In addition, not all iPSCs
colonies are fully reprogrammed and some can still express the
exogenous transgenes after several passages. The constant expres-
sion of the reprogramming genes that gave pluripotency to the
cells in the ﬁrst time could in theory result in a problematic issue
when iPSCs are driven towards the differentiation of a speciﬁc cell
phenotype. Therefore, several issues need to be considered to
ﬁnally decide if the iPSCs obtained are amenable for downstream
applications.
In summary, an ideal reprogramming method should provide:
fully reprogrammed iPSCs, medium to high reprogramming efﬁ-
ciency, iPSCs generated not longer than 1 month after gene deliv-
ery, a vector/expression system cheap, easy to produce and with
straight forward quality control tests available, reliable expression
of the 4 Yamanaka factors whose expression should shut down
after reprogramming is achieved. In addition, the method should
be clinically compatible (integration-free) if required (see Table 1).
In reality, a scenario starts to appear where, as it was for the
case of gene therapy, a particular reprogramming method would
be ideal for a given cell and not for another. In addition, the ﬁnal
use of the iPSC determines the reprogramming method of choice
since the easiest, more efﬁcient and more reliable reprogramming
methods (retrovirus-derived vectors) are the approaches of choice
for academic purposes but not for clinical applications due to
potential risks represented by the usage of genome-integrating
viruses. In other words, it takes two to dance the desired tango
Table 1
Features of an ideal reprogramming method.
The ideal reprogramming method should:
U Generate fully reprogrammed iPSCs
U Allow medium to high reprogramming efﬁciency
U Achieve fast reprogramming of cells (less than 1 month after gene
delivery)
U Include a vector/expression system:
o Easy to produce
o Cheap
o With straight-forward quality control tests available
o Able to express reproducible amounts of the 4 Yamanaka factors in
all experiments
o Allowing the shutdown of the reprogramming genes after repro-
gramming is achieved
U Be clinically compatible (integration-free) if required
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cell used as starting material.
Once the challenge of generating a bona ﬁde iPSC is met, an
even more complicated task is awaiting: the differentiation to
the desired cell type.
3. iPSCs and cell differentiation
As mentioned before, ESCs and iPSCs can potentially generate
the more than 200 different, human cell types. During develop-
ment, several factors such as transcription factors, growth factors,
and the extracellular environment direct speciﬁc genetic programs
to originate a particular cell type. The task of mimicking such con-
ditions in the lab is formidable monumental. Due to the plethora of
data coming from developmental biology, embryology and other
areas of research studying the phenomenon of cell differentiation
and the studies conducted with hESCs, it is now sometimes possi-
ble to drive the iPSC to a pathway that ends in a desired cell type.
However, not all cell types can be obtained nowadays from iPSCs or
ESCs. For example, functional hepatocytes are still not available
from these cells [65].
We will focus our analysis on neuronal differentiation since it
allows us to discuss both established protocols and procedures that
have room for improvement. For example, nowadays, it is possible
to generate neuroepithelium with high (>90%) efﬁciency. At the
same time, speciﬁc neuronal populations, such as dopaminergic
(DA) neurons (DAn), are harder to obtain. Therefore, neuronal dif-
ferentiation allows us to discuss both established protocols and
procedures that have room for improvement.
3.1. iPSCs-derived neurons
IPCs-derived neurons represent a useful tool that could provide
a ﬁrst understanding for physiological and pathological processes
of the central nervous system. To achieve this complex goal obtain
neurons from iPSCs, several research groups had developed differ-
entiation protocols to obtain diverse neurons phenotypes by
manipulation of culture conditions, such as type of coating and
speciﬁc combinations of differentiation factors. In this case, the
efﬁciency to obtain the desired neuronal phenotype is crucial in
order to perform downstream experiments: i.e., preparations with
low number of the required neurons will serve for imaging analysis
or single cell studies, whereas cultures with over 90% of homo-
geneity could be utilized for robust molecular biology techniques.
3.1.1. Neuroepithelial culture
It is nowadays feasible to obtain a neuroepithelial culture with
consisting of over more than 90% of neurons [13,36,47] and own
unpublished data). Most of these neurons are glutamatergic and
GABAergic and less than 10% of dopaminergic and serotonergicneurons are also routinely present ([36] and own unpublished
data)). In addition to culturing these cells in a monolayer, it is pos-
sible to generate them in suspension, in a 3D fashion. This culture
system allows studying developmental processes [13,36,47].
Moreover, from human iPSCs, Lancaster and colleagues were able
to generate cerebral organoids, a three dimensional structure that
contains areas which resemble speciﬁc independent brain regions
such as cerebral cortex ([36] and Fig. 1)). Using this model, neu-
ronal differentiation analysis from patients with microcephaly
could be performed [36]. The facts that these regions contain neu-
ronal progenitors which can reach a mature state allow the oppor-
tunity for example to study cell–cell interactions, time course of
cell differentiation in both normal and pathological conditions. It
is foreseen that this technical development will facilitate the
comprehension of the processes involved in various brain diseases
by simplifying the variables associated with the animal models
traditionally used.
3.1.2. Speciﬁc neuronal differentiation
As stated above, speciﬁc neuronal phenotypes can be obtained
with less efﬁciency. Both types of cortical neurons, glutamatergic
and GABAergic cortical neurons were successfully derived from
human iPSCs. A preparation was obtained with 70–75% of gluta-
matergic and 10–20% of GABAergic neurons, respectively
[5,58,86]. This is an attractive approach for in vitro studies of
physiological and pathological mechanisms involving the cerebral
cortex cortical neurons [70,5,58,86].
Shimada and colleagues reported differentiation to serotoniner-
gic neurons from PSC with 80% of efﬁciency. The study and
characterization of this neuronal type could be useful to under-
stand the development of psychiatric conditions, such as obsessive–
compulsive disorder, depression and impulsivity [71,58].
Motor neurons are the other type of neuron derived from iPSCs
which could represent a useful in vitro model for understanding
physiological process involved in motor system. Additionally, a
disease-modeling-approach could be used for development of
effective therapies. Furthermore, it has opened opportunities to
cell therapy strategies for motor neuron disease [23,58].
3.1.2.1. Methods of dopaminergic differentiation. Dopaminergic dif-
ferentiation from PSCs, resembling bona ﬁde A9 neurons, is instru-
mental to study Parkinson’s disease and for the development of
therapies against this pathology. Dopaminergic differentiation
from PSCs was has already been achieved by several research
groups [90,16,35,61,8,42,58].
One strategy for dopaminergic differentiation involves the
generation of embryoid bodies (EBs) followed by selection and
expansion of nestin-positive cells and treatment with sonic
hedgehog (Shh) and ﬁbroblast growth factor 8 (FGF8). This is a
complex multiple-step method which could generate up to 30%
of tyrosine hydroxylase (TH) (the limiting enzyme in dopamine
synthesis)-positive cells [37].
Cho and colleagues have obtained mature and functional DAn
from homogeneous spherical neural masses (SNMs) derived from
hESCs with an efﬁciency of 86%. The authors stated that DA differ-
entiation protocol based on SNMs usages have various advantages
such as: SNMs can be expandable for several passages and DA dif-
ferentiation can be achieved in 14 days. Also the protocol devel-
oped did not use any type of genetic modiﬁcation or co-culture
with feeder cells. This represents a safer method for cell transplan-
tation. However, histological analysis of grafts showed that after
12 weeks post transplantation, only 2.7% of the surviving cells
were TH positive cells from which a small population were positive
for DAT (dopamine active transporter) suggesting that the
maturation state of the majority of cells present in the graft was
incomplete at the time selected for this study [16].
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tems with meningeal cells; glial cells or stromal cells [31,6,22]
(see Fig. 1 for illustration). Co-culture with stromal cell lines such
as PA6 or MS5 cells, which have a stromal-derived inducing activ-
ity (SDIA) is a simpler and faster method than the EBs strategy [31].
Using this protocol dopaminergic differentiation from PSCs was
successfully reported with efﬁciencies between 54% and 87%
[31,90,91,87] (see Fig. 1 for illustration).
In order to elucidate the molecular mechanism of DA induction,
various research groups tried to establish which factors were
involved in DA differentiation. For example, GDNF, a survival factor
for dopamine neurons was able to duplicate the efﬁcacy of
DA-differentiation using the PA6 co-culture system in hESCs [6].
It was also observed that cell-surface components and soluble fac-
tors had DA activity [31]. It has been shown that generation of DAn
from hESCs could be obtained using PA6-conditioned medium
(CM) with fewer efﬁciency than PA6 co-cultures methods [87].
Interestingly, the addition of heparin to PA6-CM increased the per-
centage of dopaminergic neurons generated, suggesting that the
biological activity of the soluble factors required for survival and
dopaminergic differentiation of ESCs could be stabilized and/or
activated by heparin addition [22,87]. Related to this fact, it was
demonstrated that while PA6-CM is not able to induce dopaminer-
gic differentiation in ESCs with high efﬁciency, it could differenti-
ated neural stem cells (NSCs) to the DA phenotype with a 25% of
efﬁciency [78]. This observation suggests that PA6-CM contains
the necessary factors for dopaminergic induction from NSCs, while
the cell survival factors required for ESCs could be active only with
heparin addition. Based on results obtained from microarray
analysis from the PA6 line and NSCs, dopaminergic differentiation
from NSCs was achieved with a protocol based on a treatment
with Shh/FGF8 factors and subsequently, with BDNF and
GDNF-supplemented medium [78]. Optimization of the PA6-CM
differentiation method includes addition of BDNF and GDNF which
favors cell survival and dopaminergic differentiation [80]. In addi-
tion, it was found that Amiodarone can selectively kill ESCs but
spare DA precursors, increasing DA differentiation efﬁciency [21].
While these works suggested that PA-6 co-culture or PA6-CM
are simple and fast strategies, they are not totally compatible with
the development of good manufacturing practices (GMPs) proto-
cols, which are mandatory for the generation of clinical-grade DA
neurons. Related to that issue, X. Zeng’s research group was
capable to obtain functional dopaminergic neurons under deﬁned
media, a protocol compatible with a GMP-compliant process [79].
Reports from Kirks and colleagues suggested that Lmx1a and
FoxA2 expression is an important factor for the generation of
dopaminergic neurons with A9/A10 phenotype [35]. Based on this
fact, Liu and colleagues optimized cell culture conditions in order
to increase the percentage of DA cells expressing Lmx1A and
FoxA2. This strategy allowed DA differentiation in a shorten period
of time with less variability [42]. Using this protocol and also the
PA6-CMmethod, we were able to obtain TH/TuJI positive cells from
hNSCs (Fig. 1).
Two key, mostly neglected issues need to be solve in order to
move forward to a clinical setting: the viability after thawing and
the deﬁnition of the degree of maturity of the dopaminergic
precursor to be transplanted.
The transplantation of fully mature DAn into the brain has
resulted in very poor survival [3]. This fact is supposed to originate
from the damage to fully differentiated neurons with relatively
long processes when they are harvested from the culture dish
and the inability or extreme difﬁculty of mature neurons to inte-
grate into the host parenchyma. Therefore, there is a consensus
that DA precursors should be transplanted and allow their ﬁnal
maturation step in vivo. However, few studies have addressed this
issue. Peng and colleagues have determined that DA precursorsharvested 14 days after the beginning of the differentiation proto-
col can mature, survive and ameliorate motor symptoms in a rat
model of Parkinson’s disease [56].
In a fundamental study, frozen and cryopreserved dopaminergic
precursors were tested in cell transplants on a 6-OHDA animal
model of Parkinson’s disease. The results obtained showed similar
motor behavior recovery for both types of cellular preparations
using a speciﬁc protocol. Moreover, it was observed that
frozen-DA precursors were able to differentiate to a mature state
equally to fresh preparations of DA precursors [42,56]. Therefore,
these publications indicate that it is feasible to prepare DA precur-
sors preparations at a differentiation step that allowed survival and
amenable to freezing and thawing. This last step is crucial since,
most of the cases, it is envisaged that the place of DA precursors
production could be at a long distance from the site of cell trans-
plantation into the patient.
4. Cellular reprogramming based models of human
neurological disorders
iPSCs-derivedneurons representapotential tool fordiseasemod-
eling, and identiﬁcation of genes as therapeutic targets. Likewise,
this technology opens a new perspective for drug discovery, since
it allows the possibility to generate iPSCs from patients which could
serve as a speciﬁc disease model for compounds screening.
Various neurological disease models have already been devel-
oped using iPSC technology. Research works for iPSCs generation
and neuronal differentiation were reported from Alzheimer’s dis-
ease (AD), Rett syndrome, Huntington’s disease, spinal muscular
atrophy, amyotrophic lateral sclerosis, schizophrenia, Down’s syn-
drome, Parkinson’s disease, etc. [14]. The model of AD includes
iPSCs differentiation not only towards neuronal phenotypes such
as cortical and cholinergic neurons and neural precursor cells but
also astrocytes [28,34,88,26].
Also, a consortium for Huntington disease (HD) has developed
14 iPS cell lines from HD patients in order to obtain neuronal cells
and characterize cell vulnerability and alterations in metabolic and
electrophysiological features that could be related to HD [9].
In addition, Li and colleagues had generated 22 iPSCs lines from
patients with familial amyotrophic lateral sclerosis (fALS), which
includes several types of mutations being therefore a useful model
for analyze molecular pathways involved in fALS development [40].
More than 10 publications are available describing the func-
tional and morphological characteristics of iPSCs-derived DA neu-
rons from PD patients. This proliﬁc activity allows an in-depth
comparison of the results obtained which are relevant to drug dis-
covery strategies for this disease. To obtain a better understanding
of the implications of those results, a brief introduction to PD is
provided.
4.1. Parkinson’s disease and in vitro models using iPSC-derived DA
neurons
PD is a neurodegenerative disorder that affects more than 1% of
people over the age of 60. The principal feature of this disease is
the progressive loss of DAn of the nigrostriatal system, causing
the motor symptoms observed in these patients [33,49]. At the
moment, approved treatments include pharmacological replace-
ment of dopamine and electrical inhibition of speciﬁc areas such
as the sub-thalamic nucleus. Oral intake of DA precursors or ago-
nists can control motor symptoms in PD patients for several years,
but thereafter many motor and non-motor complications arise. In
addition, there is no treatment that protects DAn from cell death
and halt disease progression. Thus, there is an urgent need to
develop new drugs and novel therapeutic strategies that prevent
the progressive loss of DAn [38,51,57].
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by X. Zeng’s research group. In order to generate a platform of DAn
for drug screening, hNSCs were obtained from hESCs and hiPSCs.
To validate this system, a set of several candidate neuroprotective
agents were tested in a model of cell neurotoxicity by MPP+, a
speciﬁc neurotoxin for DAn. The results of this study showed that
from a total of 44 compounds tested only a third were neuropro-
tective. Interestingly, molecules which were reported previously
as cytoprotective in vitro but failed in clinical trials, did not have
neuroprotective action in this model, suggesting that DA neurons
derived from PSCs may represent an accurate system for drug test-
ing [55].
iPSCs-derived dopaminergic neurons from patients with spo-
radic and genetic forms of PD were generated in order to study
molecular and cellular alterations that could lead to the develop-
ment of this neuropathology [91,7,49,68,10,27,63,60,62,64,67,69].
Vulnerability and/or an increased response to oxidative stress,
alpha-synuclein accumulation, alterations in autophagy mecha-
nism, changes in mitochondrial morphology and function are all
previously known features of DAn pathology. These features were
studied in the iPSC-derived models. A summary of this effort is
summarized in Table 2. Susceptibility to oxidative stress and/or
an increased response to oxidative stress was proven in 5 of the
studies (4, 6, 8, 10 and 11); alpha-synuclein accumulation was
observed in 7 studies (1, 2, 4, 5, 8, 9 and 10); changes in autophagy
or lysosome function was detected in 2 publications (1 and 2);
alterations in mitochondrial function, in 5 manuscripts (3, 6, 7, 8,
and 9) and morphological alterations in 2 (2 and 5).
The studies from iPSCs-derived neurons from PD patients can be
divided according to the form of PD studied (sporadic or
genetically-related to genes such as alpha-synuclein, LRRK-1,
PARK-2 or PINK-1), where they focused on a spontaneous or
treatment-triggered phenotype and there was an attempt to test
a therapeutic intervention on these cells (see Table 2). Some inter-
esting features emerge from individual as well as by comparing
several studies.
Investigating iPSC-derived DA neurons from idiopathic PD
patients, Sanchez-Danes and colleagues discovered that a sponta-
neous phenotype was not observable at 30 days of culture [63].
However, if cells were left to grow for 75 days, spontaneous alter-
ations typical of PD such as increased apoptosis and accumulation
of alpha-synuclein emerged [63]. It is remarkable that time in cul-
ture can favor the occurrence of pathological landmarks of PD
while aging is the highest risk factor for PD. This concordance
may indicate that aging in culture can be used to study a chronic
process in the cells that leads to morphological and functional
alterations.
Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene is
the most prevalent in the genetically-linked PD as well as in spo-
radic forms [84]. However, its function is not fully understood.
DAn from iPSCs of patients with mutations in the LRRK2 gene
(LRRK2mut) showed an increment in mitochondrial DNA damage
together with mitochondrial dysfunction, and cellular vulnerabil-
ity. Also, genes involved in oxidative stress pathways were upreg-
ulated in DAn carrying the LRRK2-G2019S mutation [49,64].
Mutations in gene coding for the ubiquitin ligase Parkin
(PARK2) are linked to familial Parkinson’s disease. One of the main
functions of Parkin is to maintain mitochondrial function and
integrity. First, a decrease in the efﬁcacy of dopaminergic differen-
tiation between NSCs of PD patients carrying the mutations and
control subjects was observed. Then, alterations in mitochondrial
volume fraction and molecular pathways related with mitophagy
(degradation of mitochondria by autophagy) were also detected
in DAn derived from iPSCs-PARK2mut, which is consistent with
the biological function of PARK2 [69].Other iPSC-derived PD model is based on PINK1 (PTEN-induced
putative kinase 1) gene mutations which are also related to PD
development. PINK1 is a mitochondrial protein which function is
related to cellular protection against stressors agents that could
cause mitochondrial damage. DA neurons were generated from
iPSCs from patients carrying the PINK1-Q456X mutation
(iPSCs-PINK1mut). Cellular vulnerability to different stressors
agents were increased in DAn derived from iPSCs-PINK1mut. This
was accompanied by increased levels of mitochondrial reactive
oxygen species and alterations in mitochondrial functions.
Moreover, pharmacological treatment with antioxidant com-
pounds prevented cellular susceptibility to stressors agents [11].
Taken all these results together, these models using different
reprogramming and differentiation methods are validated by these
common ﬁndings. Once validated, they serve as a cellular experi-
mental set-up to address new questions on PD pathophysiology,
target discovery and drug screening. This approach is certainly pro-
viding a new way to understand this and other diseases that adds
the traditional post-mortem analysis of brain samples or disease
animal models with the advantage of a study conducted while
the disease is progressing in the patient, providing a window of
opportunity for, sooner or later, therapeutic interventions.
5. Conclusions and perspectives
Considering that S. Yamanaka’s seminal work on murine cell
reprogramming was published in 2006, the Nobel Prize for
Medicine or Physiology of 2012 to his work was one of the fastest
to be conceded. Certainly, the other Nobel award winner of that
year, Dr. J. Gurdon, conducted an instrumental contribution to cell
reprogramming more than 40 years ago, highlighting the impor-
tance of previous basic research efforts in the ﬁeld. We believe that
the initial data already generated with this technology has proven
that the Nobel Prize committee was right in honouring these scien-
tists for their discoveries.
First, cell reprogramming has been reproduced by several
groups worldwide using a variety of methods. As discussed before,
we believe that the ﬁeld will come to a conclusion similar to the
gene therapy ﬁeld: there will be an ideal reprogramming (gene
transfer) method for a given cell, but not for all cells.
Second, iPSCs have arisen much hope concerning future
iPSC-based cell therapies. Indeed, a ﬁrst clinical trial for macular
degeneration using iPSC-derived retinal pigmented cells has
started in Japan, showing the developmental speed of the ﬁeld
[12]. Nevertheless, clinical translation is inevitably long and
requires a tight regulation. In order to preserve the patient’s safety
and hopes, each step of clinical protocol must be deeply discussed.
Thereby, each step achieved would have a high chance to provide
valuable evidence, without the risk of producing a negative impact
on the ﬁeld. Again, lessons could be learned from the gene therapy
ﬁeld where adverse effects or deviations from the approved proto-
col in three clinical trials out of several thousands, have put a cone
of shadow in that ﬁeld for several years. In particular, the stem cell
therapy ﬁeld is already primed with offers of unproven, ineffective
and potentially dangerous stem cell treatments, raising the hope of
patients and the hype of media. In this context, a critical discussion
of future steps is mandatory so that clinical application of
iPSC-derived treatments reaches a safe harbour.
Third, notwithstanding the future impact of this technology on
cell therapy, a ﬁrst, clear and potent effect on neurological diseases
arises from the application of this technology to model diseases in
a dish. The ability to have neurons available in the laboratories
from neurological patients was unrealistic ten years ago.
Nowadays, the generation of neuroepithelium from iPSCs is rela-
tively simple and straightforward. Obtaining the desired neuron
Table 2
PD models using iPSC-derived DA neurons.
Disease Source Cell type Cell
characterization
Spontaneous disease phenotype Disease phenotype after treatment Treatment tested Refs.
Parkinson’s
disease
(PD)
GBA mutation PD
iPSC
DAn TH+; Foxa2+;
NURR1+; GIRK2+
and VMAT2+ cells
Increased levels of glucosylceramide and
a-synuclein. Alterations of autophagic
and lysosomal mechanism.
Dysregulation of calcium homeostasis.
Cell vulnerability
– Genetic repair of the GBA
mutation reduced patological
features
[1]
Non-PD control
LRRK2 G2019S
mutation PD iPSC
DAn bIII-tubulin+ and
TH+ cells
Morphological alterations, anormal
accumulation of a-synuclein and
disfuntional autophagic clearance
mechanism in PD-iPSC-derived DAn
– – [2]
Idiopatic PD
Non-PD control
LRRK2 G2019S
mutation PD iPSC
Neuroprogenitor
cells and neural
cells
Synapsin+;
alpha-
synuclein+;
GABA+; TH+ and
VMAT2+ cells
Mitochondrial DNA lesions – Genetic repair of the LRRK2
G2019S mutation reduced
mtDNA damage
[3]
LRRK2 R1441C
mutation PD iPSC
Non-PD control
LRRK2 G2019S
mutation PD iPSC
DAn bIII-tubulin+;
TH+; Foxa-2;
Pitx3; and
Nestin+ cells
Higher expression of oxidative stress
response genes and a-synuclein in DAn
derived from LRRK2 G2019S iPSCs
Increased susceptibility to H2O2 or 6-OHDA
treatments in DAn derived from iPSCs of LRRK2
G2019S
– [4]
Non-PD control
LRRK2 G2019S
mutation PD iPSC
DAn MAP2+;TH+ and
Foxa-2
Alterations in neurite outgrowth. High
level expression of a-synuclein, TAU,
MAPT and pERK
Increased cell vulnerability to 6-OHDA or rotenone
treatments in DAn derived from iPSCs of LRRK2
G2019S
ERK inhibition lead to
cytoprotection of DAn derived
from iPSCs of LRRK2 G2019S and
neurite outgrowth
[5]
Non-PD control
PINK1 Q456X
mutation PD iPSC
Neural cells
including DA
neurons
bIII-tubulin+;
TH+ and Foxa-2
cells
Differential vulnerability of human
neural cells, neurons and DAn carrying
PD associated mutations
Vulnerability to cellular oxidative stress in neural
cells derived from iPSCs of PINK1 mutated form.
Cellular stressors used: valinomycin; MPP+; 6OHDA;
concanamycin A; H2O2; MG132; CCCP
Coenzyme Q10, rapamycin or
the LRRK2 kinase inhibitor
GW5074 showed protective
effect
[6]
LRRK2 G2019S
mutation PD iPSC
Mitochondrial alterations in neural cells
derived from iPSCs of LRRK2 mutated
formLRRK2 R1441C
mutation PD iPSC
Non-PD control
PARK2 mutation PD
iPSC
DAn bIII-tubulin+;
TH+ and Foxa-2
cells
Decrease of TH+ cells numbers in iPSCs
with PARK2 mutation. Mitochondrial
alterations
– – [7]
Non-PD control
PARK2 deletion PD
iPSC
DAn bIII-tubulin+ and
TH+ cells
Increased ROS levels. Mitochondrial
morphological alterations. Accumulation
of a-synuclein
– – [8]
Non-PD control
PINK1 Q456X
mutation PD iPSC
DAn bIII-tubulin+ and
TH+ cells
Alterations in mitochondrial biogenesis
and increases in mitochondrial copy
number
mtDNA alterations after loss of mitochondrial
membrane potential induced by valinomycin
– [9]
PINK1 V170G
mutation PD iPSC
Non-PD control
A53T a-synuclein
mutation PD iPSC
DAn bIII-tubulin+;
TH+; Girk2+ and
Lmx1a+ cells
Accumulation of oligomerized a-
synuclein and Lewy neurite/body-like
deposition
Accumulation of ROS/RNS to treatment with
mitochondrial toxins (H2O2; MPP+;paraquat;
rotenone; manganese ethylenebisdithiocarbamate)
Inhibition of NOS protects DAn
derived from A53T a-synuclein
iPSC from cell death. Screening
of several compounds
[10]
Non-PD control
SNCA triplication
(Trpl-HDF) PD iPSC
DAn bIII-tubulin+;
TH+; Girk2+;
Foxa-2 and
Lmx1a+ cells
Accumulation of a-synuclein, increase of
oxidative stress markers
Cell vulnerability to oxidative stress induced by H2O2 – [11]
Non-PD control
1, [67]; 2, [63]; 3, [64]; 4, [49]; 5, [60]; 6, [10]; 7, [69]; 8, [27]; 9, [68]; 10, [62]; 11, [7].
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some cases. Levelling this up to the production of clinical grade
cells requires speciﬁc expertise that is usually not in the comfort
zone of basic research scientists and therefore this crucial step calls
for a team effort. Nevertheless, due to the plethora of data obtained
in the last decades, several differentiation protocols have already
been established and valuable data have been obtained for many
diseases. Especially the studies on PD, have provided irrefutable
evidence that this technology can be indeed used for disease
modeling.
In conclusion, cell reprogramming came here to stay and move
forward the neurology ﬁeld as no other time in the last century.
Hopefully, the coordinated action of scientists, regulators, physi-
cians, legislators and bioethicists will provide a clear pathway to
translate the enormous potentiality of this technology into real,
clinically-relevant results in terms of cell therapy, identiﬁcation
of therapeutic targets or drug discovery for neurological diseases.
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